BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 32805254)

  • 1. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.
    Hatami E; Nagesh PKB; Jaggi M; Chauhan SC; Yallapu MM
    Eur J Pharmacol; 2020 Dec; 888():173486. PubMed ID: 32805254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.
    Chougule MB; Patel A; Sachdeva P; Jackson T; Singh M
    PLoS One; 2011; 6(11):e27394. PubMed ID: 22102891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
    Feng F; Wang B; Sun X; Zhu Y; Tang H; Nan G; Wang L; Wu B; Huhe M; Liu S; Diao T; Hou R; Zhang Y; Zhang Z
    Cancer Biol Ther; 2017 Jan; 18(1):51-62. PubMed ID: 28055291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling.
    Wang LH; Li Y; Yang SN; Wang FY; Hou Y; Cui W; Chen K; Cao Q; Wang S; Zhang TY; Wang ZZ; Xiao W; Yang JY; Wu CF
    Br J Cancer; 2014 Jan; 110(2):341-52. PubMed ID: 24300974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer.
    Zhang R; Ru Y; Gao Y; Li J; Mao S
    Drug Des Devel Ther; 2017; 11():2631-2642. PubMed ID: 28919713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
    Higgins B; Kolinsky K; Smith M; Beck G; Rashed M; Adames V; Linn M; Wheeldon E; Gand L; Birnboeck H; Hoffmann G
    Anticancer Drugs; 2004 Jun; 15(5):503-12. PubMed ID: 15166626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc oxide nanoparticles (ZnO NPs) combined with cisplatin and gemcitabine inhibits tumor activity of NSCLC cells.
    Hu C; Du W
    Aging (Albany NY); 2020 Nov; 12(24):25767-25777. PubMed ID: 33232271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibitory effects of a combination of rmhTRAIL and gemcitabine on human non-small cell lung cancer cell line NCI-H460 cells in vitro and in vivo].
    Tang CH; Liu XQ; Yang SF; Zhu B; Gao HJ
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):808-12. PubMed ID: 19173823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biweekly cisplatin and gemcitabine with two different doses in non small cell lung cancer patients: A retrospective singlecenter experience.
    Dogan E; Ucar M; Sakalar T; Derin S; Bozkurt O; Inanc M; Ozkan M
    J BUON; 2018; 23(4):1070-1076. PubMed ID: 30358213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of NF-κB signaling and P-glycoprotein function by gambogic acid synergistically potentiates adriamycin -induced apoptosis in lung cancer.
    Wang LH; Yang JY; Yang SN; Li Y; Ping GF; Hou Y; Cui W; Wang ZZ; Xiao W; Wu CF
    Curr Cancer Drug Targets; 2014; 14(1):91-103. PubMed ID: 24245692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
    Yu Y; Wang J; Xia N; Li B; Jiang X
    Oncol Rep; 2015 Apr; 33(4):1683-90. PubMed ID: 25633045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of artesunate and carboplatin exerts a synergistic anti-tumour effect on non-small cell lung cancer.
    Wang Z; Wang Q; He T; Li W; Liu Y; Fan Y; Wang Y; Wang Q; Chen J
    Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):1083-1091. PubMed ID: 32072678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.
    Kim MK; Jeon YK; Woo JK; Choi Y; Choi DH; Kim YH; Kim CW
    Mol Cancer; 2011 Aug; 10():98. PubMed ID: 21843371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of the combination of gemcitabine hydrochloride (LY188011) and cisplatin in non-small-cell lung cancer: 3-week schedule.
    Kunikane H; Kurita Y; Watanabe K; Yokoyama A; Noda K; Fujita Y; Yoneda S; Nakai Y; Niitani H
    Int J Clin Oncol; 2001 Dec; 6(6):284-90. PubMed ID: 11828947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific inhibitor of Notch‑3 enhances the sensitivity of NSCLC cells to gemcitabine.
    Hu BD; Guo J; Ye YZ; Du T; Cheng CS; Jiang Q; Liu RN; Zhang YB
    Oncol Rep; 2018 Jul; 40(1):155-164. PubMed ID: 29781034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic activity of combination therapy with PEGylated pemetrexed and gemcitabine for an effective cancer treatment.
    Vandana M; Sahoo SK
    Eur J Pharm Biopharm; 2015 Aug; 94():83-93. PubMed ID: 25968494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
    Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X
    J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine.
    Vansteenkiste JF; Vandebroek JE; Nackaerts KL; Weynants P; Valcke YJ; Verresen DA; Devogelaere RC; Marien SA; Humblet YP; Dams NL;
    Ann Oncol; 2001 Sep; 12(9):1221-30. PubMed ID: 11697832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis.
    Chen W; Tan X; Yang Q; Fang Z; Xu Y
    Cell Signal; 2022 Jun; 94():110326. PubMed ID: 35367362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.